Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Checkpoint Capital L.P. acquired 9,011 shares of Immunocore Holdings PLC valued at approximately $267,000, making it the company's 13th largest position.
• Other institutional investors, including Banque Transatlantique and Frazier Life Sciences Management, have also increased their stakes in Immunocore during the first quarter.
• Immunocore reported a revenue of $130.65 million for the last quarter, beating analyst estimates as the company continues to develop immunotherapies for cancer and other diseases.

Checkpoint Capital L.P. bought a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 9,011 shares of the company's stock, valued at approximately $267,000. Immunocore comprises approximately 0.1% of Checkpoint Capital L.P.'s holdings, making the stock its 13th biggest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMCR. GF Fund Management CO. LTD. purchased a new position in Immunocore in the fourth quarter valued at about $25,000. Oppenheimer Asset Management Inc. purchased a new position in Immunocore during the first quarter valued at $225,000. Banque Transatlantique SA purchased a new stake in Immunocore during the first quarter valued at approximately $278,000. Tema Etfs LLC bought a new position in Immunocore in the 4th quarter valued at $330,000. Finally, Barclays PLC boosted its position in Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after acquiring an additional 19,663 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 4th. Jefferies Financial Group assumed coverage on shares of Immunocore in a research report on Monday, August 25th. They issued a "buy" rating and a $48.00 price target on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Finally, Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Immunocore has an average rating of "Hold" and a consensus target price of $56.89.

Immunocore Stock Performance

IMCR traded down $0.51 during midday trading on Tuesday, reaching $36.14. The company's stock had a trading volume of 140,929 shares, compared to its average volume of 334,831. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $39.33. The stock has a market cap of $1.82 billion, a P/E ratio of -90.34 and a beta of 0.77. The company has a fifty day simple moving average of $33.73 and a 200 day simple moving average of $31.61. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The business had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. The firm's revenue for the quarter was up 30.0% on a year-over-year basis. Research analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.